$14.46
+0.56 (+4.03%)
BHVN News3 articles
Biohaven Shares Slide 5% as Raymond James Slashes Target on Opakalim Deal
Biohaven (BHVN) shares dropped 4.9% to $16.12 after Raymond James cut its price target to $30 from $50, citing the opakalim licensing deal that brings $400M cash but reduces upside.
Biohaven Shares Slide 7% as Investors Reassess Opakalim Deal Value
Biohaven shares fell 7.1% to $15.75, reversing nearly half of Wednesday's gains from its $400 million opakalim licensing agreement with SK Biopharmaceuticals.
Biohaven Stock Soars 25% on Trade Secret Ruling
Biohaven shares surged 25% after a federal court finalized a $4 million trade secret ruling, boosting market cap by $553 million as investors bet on platform value.